Article

Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior

Department of Psychiatry, Vanderbilt University, Nashville, TN 37232, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 03/2012; 109(14):5469-74. DOI: 10.1073/pnas.1112345109
Source: PubMed

ABSTRACT Fifty years ago, increased whole-blood serotonin levels, or hyperserotonemia, first linked disrupted 5-HT homeostasis to Autism Spectrum Disorders (ASDs). The 5-HT transporter (SERT) gene (SLC6A4) has been associated with whole blood 5-HT levels and ASD susceptibility. Previously, we identified multiple gain-of-function SERT coding variants in children with ASD. Here we establish that transgenic mice expressing the most common of these variants, SERT Ala56, exhibit elevated, p38 MAPK-dependent transporter phosphorylation, enhanced 5-HT clearance rates and hyperserotonemia. These effects are accompanied by altered basal firing of raphe 5-HT neurons, as well as 5HT(1A) and 5HT(2A) receptor hypersensitivity. Strikingly, SERT Ala56 mice display alterations in social function, communication, and repetitive behavior. Our efforts provide strong support for the hypothesis that altered 5-HT homeostasis can impact risk for ASD traits and provide a model with construct and face validity that can support further analysis of ASD mechanisms and potentially novel treatments.

0 Followers
 · 
156 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dysregulation of serotonin (5-HT) signaling underscores long-standing theories of circuit perturbations that lead to risks for mental disorders. 5-HT acts both as a morphogenetic factor during neural circuit formation and a neuromodulator of circuit plasticity in the mature CNS (Gaspar et al., 2003, Kandel, 2001 and Lesch and Waider, 2012). The 5-HT transporter (SERT) controls 5-HT signaling by limiting 5-HT availability to 5-HT receptors (Blakely and Edwards, 2012). Selective 5-HT reuptake inhibitors (SSRIs), which block SERT thus increasing 5-HT signaling, are the first-line treatments for psychiatric traits in adults. However, polymorphisms that reduce SERT gene Slc6a4 expression/functionality increase the risks for autism and depression and confer abnormal cortical anatomical architecture (Murphy and Lesch, 2008, Pezawas et al., 2005 and Veenstra-VanderWeele et al., 2012). In rodents, excessive 5-HT triggered by knocking out SERT or the 5-HT degradation enzyme monoamine oxidase A (MAOA) disrupts topographic patterning of the somatosensory barrel and visual cortex and causes anxiety-like behavior (Cases et al., 1996, Murphy and Lesch, 2008, Persico et al., 2001 and Upton et al., 2002). Furthermore, administration of SSRIs during the first 2 postnatal weeks was sufficient to confer altered CNS dendritic morphology and increased anxiety-like behavior (Rebello et al., 2014). These observations suggest that SERT exerts distinct biological roles in developing and adult CNS. The mechanism underlying SERT gene function in the developing CNS remains unclear.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Autism spectrum disorders (ASDs) are genetically and clinically heterogeneous and lack effective medications to treat their core symptoms. Studies of syndromic ASDs caused by single gene mutations have provided insights into the pathophysiology of autism. Fragile X and Rett syndromes belong to the syndromic ASDs in which preclinical studies have identified rational targets for drug therapies focused on correcting underlying neural dysfunction. These preclinical discoveries are increasingly translating into exciting human clinical trials. Since there are significant molecular and neurobiological overlaps among ASDs, targeted treatments developed for fragile X and Rett syndromes may be helpful for autism of different etiologies. Here, we review the targeted pharmacological treatment of fragile X and Rett syndromes and discuss related issues in both preclinical studies and clinical trials of potential therapies for the diseases.
    Frontiers in Cellular Neuroscience 02/2015; 9:55. DOI:10.3389/fncel.2015.00055 · 4.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Environmental enrichment aims to improve the well-being of laboratory animals and provides an opportunity to improve experimental reliability and validity. Animals raised in more stimulating environments have improved learning and memory as well as more complex brain architecture. However, the effects of environmental enrichment on motor performance, anxiety and emotional development have been poorly studied. Moreover, most investigators studying the effects of enrichment provide extremely large and complex housing conditions to maximize the likelihood of finding effects. These situations are difficult to replicate across animal facilities and are not operationally practical. In this experiment, we investigated how simple, inexpensive disposable shelterstyle enrichment items alter behavior in C57Bl/6 and 129S6 mice. Breeding pairs were established in the presence of a Ketchum "Refuge", Shepherd Shack "Dome", or no enrichment. Offspring were assessed neurobehaviorally, either just after weaning (pre-adolescent, P22-P25), or as young adults (P60-P90). Major strain differences were observed in open field activity, elevated maze exploration, and Y-maze activity levels. The presence of the Refuge and/or Dome enrichment shelters significantly altered motor activity, coordination and some measures of anxiety. Mice housed in the presence of shelters were also less dominant than control mice in a tube test assay. Our experiments provide a detailed analysis of the effects of inexpensive and practical methods of housing enrichment on biobehavioral phenotypes in these two commonly used strains of laboratory mice, and suggest that the effects of these shelters on mouse neurobiology and behavior need to be rigorously analyzed before being adopted within vivariums.
    09/2014; 5(3):185-196. DOI:10.2478/s13380-014-0228-4

Full-text (2 Sources)

Download
58 Downloads
Available from
May 15, 2014